Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...

A virus carried by 95% of adults from childhood may trigger bladder cancer decades later by damaging cells during immune ...

Despite what was previously thought, new research has shown that genetic changes alone cannot explain why and where tumors grow in those with the genetic condition neurofibromatosis type 1 (NF-1).

Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

AI-ready lab infrastructure: The Sapio Informatics Platform will give the Sanger Institute a foundation for AI native capabilities such as guided workflows and smarter access to lab data, introduced ...